NRx Pharmaceuticals (NASDAQ:NRXP) Coverage Initiated by Analysts at BTIG Research

BTIG Research started coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report issued to clients and investors on Wednesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $18.00 price target on the stock.

A number of other equities analysts have also recently weighed in on NRXP. D. Boral Capital reissued a “buy” rating and issued a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $28.25.

NRx Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ NRXP opened at $1.91 on Wednesday. The stock has a market capitalization of $32.24 million, a PE ratio of -0.89 and a beta of 1.22. The firm has a fifty day moving average of $2.50 and a 200-day moving average of $2.05. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Equities research analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. AdvisorShares Investments LLC boosted its holdings in shares of NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after buying an additional 180,229 shares during the period. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after purchasing an additional 43,135 shares in the last quarter. Millennium Management LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter valued at $61,000. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at $56,000. Finally, Townsquare Capital LLC acquired a new stake in shares of NRx Pharmaceuticals in the third quarter worth $25,000. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.